Výsledky vyhledávání - "Jean-Marie Vandenbulcke"

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

Autor: Jean-Charles Goeminne, Emmanuel Seront, Petra Boegner, Jean-Pascal Machiels, Aline Gillain, Sylvie Rottey, Jean-Marie Vandenbulcke, Philippe Glorieux, Bertrand Filleul, Vincent Verschaeve, Brieuc Sautois, Aline Van Maanen

Publikováno v: BJU International. 118:408-415

BACKGROUND: Excessive activation of the PI3K/Akt/mTOR pathway is frequently observed in transitional cell carcinoma (TCC) due to a loss of PTEN and/or activating mutation of PIK3CA. Allosteric mTOR inhibition by everolimus resulted in modest efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a7a77de8851e6ae3488df9cab50687
https://doi.org/10.1111/bju.13415

Zobrazit plný text záznamu

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy

Publikováno v: The Oncologist
The Oncologist, Vol. 21, no. 12, p. 1416-e17 (2016)

Lessons Learned Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ffbae3965bc9b13828b58054618f0d
https://hdl.handle.net/20.500.14017/27c82b0f-b698-4878-92de-961dd4853f3a

Zobrazit plný text záznamu

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Autor: D. Verhoeven, Lionel D'Hondt, N. Whenham, Olivier Feron, P. Glorieux, Catherine Dopchie, Samuel Branders, J. Schoonjans, Sylvie Rottey, Pierre Dupont, Emmanuel Seront, J-L Canon, Joseph Kerger, Marylene Clausse, Vincent Verschaeve, Jean-Marie Vandenbulcke, Jean-Pascal Machiels, Brieuc Sautois, J. C. Goeminne

Publikováno v: Annals of Oncology. 23:2663-2670

Background: This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. Patients and methods: Thirty-seven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f5ffdb9efbc7e039b5d3f6282fd904
https://doi.org/10.1093/annonc/mds057

Zobrazit plný text záznamu

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC)

Autor: Phillipe Glorieux, Jean-Marie Vandenbulcke, Vincent Verschaeve, Aline Gillain, Sylvie Rottey, Bertrand Filleul, Petra Boegner, Brieuc Sautois, Jean-Charles Goeminne, Emmanuel Seront, Jean-Pascal Machiels, Aline Van Maanen

Publikováno v: Journal of Clinical Oncology. 33:e15535-e15535

e15535 Background: Excessive activation of the PI3K/Akt/mTOR pathway is frequently observed in TCC, due to loss of PTEN and/or activating mutation of PIK3CA.We previously showed in a phase II trial...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b4650e43aa411cfa0838a156332acf7f
https://doi.org/10.1200/jco.2015.33.15_suppl.e15535

Zobrazit plný text záznamu

Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers

Autor: N. Whenham, Olivier Feron, J-L Canon, J. H. Machiels, S. Rottey, L. D'Hondt, Jean-Marie Vandenbulcke, Brieuc Sautois, Jean-Charles Goeminne, Emmanuel Seront

Publikováno v: Journal of Clinical Oncology. 29:4622-4622

4622 Background: Dysregulation of mammalian Target of Rapamycin (mTOR) pathway plays a role in TCC development. We assessed the efficacy and toxicity of Everolimus (E), an oral mTOR inhibitor, in p...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad1f13b34b0a7ef7479f9ef5b8a49248
https://doi.org/10.1200/jco.2011.29.15_suppl.4622

Zobrazit plný text záznamu

A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy

Autor: J. H. Machiels, S. Rottey, Jean-Luc Re Canon, L. D'Hondt, Jean-Marie Vandenbulcke, Brieuc Sautois, D. Verhoeven, N. Whenham, Jean-Charles Goeminne, Emmanuel Seront

Publikováno v: Journal of Clinical Oncology. 28:e15087-e15087

e15087 Background: The altered expression and activating mutations of the mammalian target of rapamycin (mTOR) pathway, and the subsequent release of angiogenic factors, play a role in transitional...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8b474e0bf11e36582459806d98783c7
https://doi.org/10.1200/jco.2010.28.15_suppl.e15087

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání